ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1702

Osteoporosis in Psoriatic Arthritis

Ali Aldei1, Shelly Chandran2, Suzanne Li2, Vinod Chandran3 and Dafna Gladman3, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: osteoporosis and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis affecting peripheral and axial joints in patients with psoriasis. The disease process in PsA comprises of complex bone involvement. A preliminary review of studies evaluating Osteoporosis in PsA provides inconsistent and conflicting results. The aim of this this study was to analyze Bone Mineral Density (BMD) in patients with (PsA), as well as to investigate its possible associations with measures of disease activity and functional capacity.

Methods: Consecutive Patients from PsA Clinic underwent BMD scan of spine L1-L4 and left Femoral Neck using Hologic Discovery A – 84248 model between March and May of 2015. BMD was expressed as g/cm2, Z-score and T-score. The percentage of patients with T-score ≤ -2.5 SD (WHO osteoporosis definition) and with Z-score ≤ -1.0 SD was calculated. Disease activity measures included: tender, swollen and damaged joint counts, patient and physician global assessment, presence of enthesitis, nail involvement and Psoriasis Area Severity Index (PASI) score. Laboratory tests included inflammatory markers ESR and CRP. Health Assessment Questionnaire (HAQ) and Short Form 36 Health Survey were used to assess functional status. Patients’ clinical, laboratory and radiological data were extracted from PsA program computer database. Statistical analysis included descriptive statistics, linear regression models and logistic regression models controlling for age.

Results: Total of 61 patients [38 males (mean age 56.57 ± 10.19 years) and 23 females (mean age 53.95 ± 10.76)] years were studied. According to WHO definition, spinal osteoporosis was found in 3% of patients and femoral neck osteoporosis in 5% of patients. Spinal osteopenia was found in 28% of patients and femoral neck osteopenia in 39%.

Disease activity measures of the recruited patients [mean (SD) or proportion] at the time of BMD assessment included: tender joint count 3.8 (7.7), swollen joint count 0.7 (1.7), clinically damaged joint count 9.1 (12.3), patient global 2.6 (0.9), physician global 1.8 (0.7), presence of enthesitis 7 (12%), nail involvement 10 (16%), ESR 14.8 (10.8), CRP 5.2 (3.3), HAQ 0.5 (0.4), Short Form -36 PCS 39.5 (10.4) and Short Form-36 MCS 50.1(12.5).

None of the clinical or laboratory features were associated with bone density either using linear regression with bone density in g/cm2measured by the BMD as outcome, or with logistic regression using low versus normal bone density as outcome.

Conclusion: In our cohort of PsA patients, prevalence of osteoporosis was not increased. BMD was not associated with disease activity or functional status.


Disclosure: A. Aldei, None; S. Chandran, None; S. Li, None; V. Chandran, None; D. Gladman, None.

To cite this abstract in AMA style:

Aldei A, Chandran S, Li S, Chandran V, Gladman D. Osteoporosis in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/osteoporosis-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoporosis-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology